By 2025, the scale of the biomedical industry in Tianjin Binhai New Area will reach 100 billion yuan

The biopharmaceutical industry is a strategic emerging industry in China.
With the intensification of aging and the advancement of a series of favorable national policies, the scale of the domestic biopharmaceutical industry market continues to expand, and there is considerable room for future development
.
This year is the first year of the "14th Five-Year Plan".
Many places such as Shanghai and Jiangsu have issued documents that clearly promote the development of the biomedical industry.
The "one wing" in the industrial innovation pattern of "one dominance and two wings"
.
It is understood that Tianjin has a solid foundation and foundation in the development of the biomedical industry.
The city is home to Tianjin’s Novo Nordisk (China) Pharmaceuticals, Tianjin Pharmaceutical Group, Tasly Holdings, Hongri Pharmaceuticals, and Servier (Tianjin) Pharmaceutical and other domestic and foreign giant companies
.
As of the end of the "Thirteenth Five-Year Plan" period, there were more than 100 listed companies and 25 listed companies in Tianjin's pharmaceutical manufacturing industry
.
Up to now, Tianjin's biomedical industry has basically formed a development pattern with its own characteristics in Wuqing, Beichen, Xiqing and Jinnan with Binhai New Area as its core
.
In 2020, the scale of Tianjin's biomedical industry will exceed 62.
7 billion yuan
.
Among them, Binhai New Area is an important base for the biomedical industry in Tianjin, focusing on six directions: synthetic biology, medical equipment, chemical pharmacy, smart medical care, modernization of Chinese medicine, and medical R&D service outsourcing
.
In recent years, Tianjin Binhai New District has made every effort to build an internationally competitive biomedical industry base, and the industry output value has been steadily increasing.
Over the years, it has attracted many high-tech and high-tech biomedical companies to land here.
At present, it has gathered various types of biomedical companies.
More than 1,500 biomedical companies have initially formed a biotechnology industry chain integrating R&D, technology transformation, manufacturing, commercial logistics, and exhibition exchanges
.
There are many subdivision fields of biomedicine.
Among them, the cell and gene industry is a big field with great potential for the biomedical industry in Tianjin Binhai New Area
.
At present, Tianjin Binhai New Area is seizing the rare opportunity of accelerating the development of the cell industry, focusing on optimizing the construction of two "Cell Valley" experimental areas in Tianjin Economic and Technological Development Zone and Tianjin Binhai High-tech Zone
.
At present, Tianjin Binhai High-tech Zone has gathered 5 national and 21 municipal industrial innovation platforms and more than 30 cell-related companies, covering cell extraction and preparation, cell storage, quality control inspection, R&D and production, application transformation, and cold chain The six aspects of logistics basically form the entire cell industry chain
.
This year, the Beijing-Tianjin-Hebei-characteristic "Cell Valley" experimental zone has been officially listed in Tianjin Economic Development Zone and Tianjin Binhai High-tech Zone, marking the gradual stepping into the "fast lane" of the biomedical industry in Binhai New Area
.
In addition, the Haihui Valley project in this area has also been officially launched, and a number of new biomedical industry highlands are emerging in Binhai New Area
.
It is reported that during the "14th Five-Year Plan" period, the biomedical industry in Binhai New Area will promote the construction of the biological manufacturing valley and the characteristic "cell valley" of Beijing-Tianjin-Hebei, focusing on key areas such as synthetic biology, vaccines, cell and gene therapy, and creating biological medicine and chemistry.
Several tens of billions of industrial clusters such as pharmaceuticals, medical equipment, and biological manufacturing
.
Data show that the output value of the biomedical industry in Tianjin Binhai New Area will reach 40.
248 billion yuan in 2020, accounting for 64.
2% of the city's biomedical output value
.
It is estimated that by 2025, the annual operating income of the biomedical industry in Binhai New Area will reach 100 billion yuan
.